"Evaluation of the Safety and Efficacy of Short-term A002 Treatment in Subjects with Acute Coronary Syndromes" (VISTA-16) (Protocol #11-10-H-04)
We are currently recruiting patients who have suffered a heart attack or chest pain to take part in a research study. You may be a candidate for the study if you:
- Have experienced a heart attack or chest pain within the last four days
- Are 40 years of age or older
- Have diabetes, history of stroke, peripheral vascular disease, previous CAGB or previous heart attack
- Are not pregnant, planning to become pregnant or breast feeding
- Are not participating in any other research studies
- Meet other qualifications
If you qualify to take part in this study, there will not be any additional cost to you. If you are interested in taking part in this study, call 305-674-2162 or send a fax to 305-674-2169.
"A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients with Elevated hsCRP" (Protocol #11-11-H-04)
We are currently recruiting patients who have suffered a heart attack to take part in a research study. You may be a candidate if you:
- Have a history of Myocardial Infarction more than 30 days ago
- Are older than 18 years of age
- Other requirements apply
If you qualify to take part in this study, there will not be a compensation for your participation. If you are interested in taking part in this study, call 305-674-2162 or send a fax to 305-674-2169.
"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multinational Trial to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction" (Protocol #11-19-H-04)
We are currently recruiting patients who have suffered a heart attack 1 to 3 years ago to take part in a research study. You may be a candidate for the study if you:
- Are 50 years of age or older
- Are currently taking aspirin daily (75 to 150 mg dose)
- Have diabetes mellitus, or history of multivessel coronary artery disease (CAD), or chronic, non-end stage renal dysfunction
- Are not pregnant, planning to become pregnant or breast feeding
- Are not participating in any other research studies
- Meet other qualifications
If you qualify to take part in this study, there will not be any additional cost to you. If you are interested in taking part in this study, call 305-674-2162 or send a fax to 305-674-2169.
"A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated with Tyvaso® (treprostinil) Inhalation Solution" (Protocol #11-20-H-05)
We are currently recruiting patients being treated for pulmonary arterial hypertension (PAH) to take part in a research study. You may be a candidate for the study if you:
- Have pulmonary arterial hypertension (PAH) and are being treated with Tyvaso® (trepostinil) Inhalation Solution or other treatment(s) for PAH
- Are 18 years of age or older
- You understand that you are being asked to take part in an observational study and agree to take part
- You agree to answer questions regarding how you have been feeling when you see your study doctor (about every 3 months) or by phone
If you qualify to take part in this study, there will not be any additional cost to you. If you are interested in taking part in this study, call 305-674-2162 or send a fax to 305-674-2169.
PRE-DETERMINE Study: Biologic Markers and Sudden Cardiac Death (Protocol #10-28-H-09)
The Division of Cardiology is currently recruiting patients who have suffered a heart attack to participate in a research study. You may be a candidate for the study if you:
- Have History of Myocardial Infarction, or
- Have Myocardial Revascularization, and
- Are older than 18 years old.
- Other criteria apply
Please call 305-674-2121 ext. 50434 to learn if you might be eligible to take part in this study. Fax communications can be sent to 305-674-2169.
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (Protocol #09-11-H-02)
We are currently recruiting patients who have suffered a heart attack within the last week into a stem cell clinical research trial. You may be a candidate for the trial if you...
- Have experienced your first heart attack within the last week
- Are 21 to 85 years old
- Are not pregnant, planning a pregnancy or breast feeding
- Are not participating in any other research studies
- Are not allergic to MRI dye, pork or beef products
- Other criteria apply
If you qualify to take part in this study, there will not be any additional cost to you. Please call 305-674-2162 to learn if you might be eligible to take part in this study. Fax communications can be sent to 305-674-2169.
For more information about participating in this trial, please visit: www.Osiris.com
Trial to Assess Chelation Therapy - TACT (Protocol #09-06-H-01)
- Have you ever had a heart attack?
- Are you age 50 or older and non-smoker?
You or someone you know may be eligible to take part in a large international research study of an alternative treatment - chelation therapy and vitamin therapy. The Trial to Assess Chelation Therapy (TACT) is a randomized, double-blind, placebo controlled study that will determine whether or not chelation therapy is a safe and effective treatment for cardiovascular disease. If you qualify to take part in this study, there will not be any additional cost to you. Please call 305-674-2162 for more information.
Share this with your friends
